These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26725668)

  • 1. [Mitochondrial DDS Opens Innovative Pharmaceutics].
    Yamada Y
    Yakugaku Zasshi; 2016; 136(1):55-62. PubMed ID: 26725668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeting mitochondria: innovation from mitochondrial drug delivery system (DDS) to mitochondrial medicine].
    Yamada Y; Harashima H
    Yakugaku Zasshi; 2012; 132(10):1111-8. PubMed ID: 23037696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
    Yamada Y
    Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.
    Yamada Y; Harashima H
    Handb Exp Pharmacol; 2017; 240():457-472. PubMed ID: 27830347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases.
    Yamada Y; Harashima H
    Adv Drug Deliv Rev; 2008; 60(13-14):1439-62. PubMed ID: 18655816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
    Yasuzaki Y; Yamada Y; Harashima H
    Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
    Yamada Y; Harashima H
    Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Nanocarrier System for Mitochondrial Delivery Targeted to a Pancreatic Beta Cell].
    Yamada Y
    Yakugaku Zasshi; 2019; 139(1):41-45. PubMed ID: 30606927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Power of mitochondrial drug delivery systems to produce innovative nanomedicines.
    Yamada Y; Satrialdi ; Hibino M; Sasaki D; Abe J; Harashima H
    Adv Drug Deliv Rev; 2020; 154-155():187-209. PubMed ID: 32987095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial delivery of bongkrekic acid using a MITO-Porter prevents the induction of apoptosis in human HeLa cells.
    Yamada Y; Nakamura K; Furukawa R; Kawamura E; Moriwaki T; Matsumoto K; Okuda K; Shindo M; Harashima H
    J Pharm Sci; 2013 Mar; 102(3):1008-15. PubMed ID: 23315986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.
    Yamada Y; Harashima H
    Mitochondrion; 2013 Sep; 13(5):526-32. PubMed ID: 23000575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in Promoting Mitochondrial Transplantation Therapy.
    Yamada Y; Ito M; Arai M; Hibino M; Tsujioka T; Harashima H
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
    Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
    Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion.
    Yamada Y; Akita H; Kamiya H; Kogure K; Yamamoto T; Shinohara Y; Yamashita K; Kobayashi H; Kikuchi H; Harashima H
    Biochim Biophys Acta; 2008 Feb; 1778(2):423-32. PubMed ID: 18054323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
    Yamada Y; Harashima H
    Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
    Furukawa R; Yamada Y; Harashima H
    Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver.
    Yamada Y; Nakamura K; Abe J; Hyodo M; Haga S; Ozaki M; Harashima H
    J Control Release; 2015 Sep; 213():86-95. PubMed ID: 26160304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control.
    Yamada Y; Sato Y; Nakamura T; Harashima H
    J Control Release; 2022 Aug; 348():357-369. PubMed ID: 35623492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for screening mitochondrial fusogenic envelopes for use in mitochondrial drug delivery.
    Yamada Y; Harashima H
    Methods Mol Biol; 2014; 1141():57-66. PubMed ID: 24567130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial drug delivery and mitochondrial disease therapy--an approach to liposome-based delivery targeted to mitochondria.
    Yamada Y; Akita H; Kogure K; Kamiya H; Harashima H
    Mitochondrion; 2007; 7(1-2):63-71. PubMed ID: 17296332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.